Literature DB >> 8874075

Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.

R Snoeck1, G Andrei, E De Clercq.   

Abstract

Drug-resistant human cytomegalovirus (HCMV) strains were selected in human embryonic lung (HEL) fibroblasts under pressure of the (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC) and adenine (HPMPA), the 2-phosphonylmethoxyethyl (PME) derivative of 2,6-diaminopurine (PMEDAP), ganciclovir (GCV), acyclovir (ACV), and foscarnet (PFA). Drug susceptibility profiles of the different drug-resistant (i.e., GCVr, HPMPCr, HPMPAr, PFAr, ACVr, and PMEDAPr) strains were determined in HEL cells. A considerable degree of cross-resistance against GCV, HPMPC, and HPMPA occurred with GCVr, HPMPCr, and HPMPAr strains. No changes in susceptibility to 9-(2-phosphonylmethoxyethyl)adenine (PMEA), PMEDAP, ACV, or PFA were detected for the HPMPCr, HPMPAr, and GCVr strains when compared to the wild-type virus. On the other hand, a significant degree of cross-resistance was noted with the PMEDAPr, PFAr, and ACVr strains against PMEA, PMEDAP, PFA, and ACV. NO differences in susceptibility to HPMPC, HPMPA and GCV were observed for the ACVr, PFAr, and PMEDAPr strains relative to the wild type. The drug susceptibility profiles of the different resistant strains point to a common mechanism of HCMV resistance to PFA and the PME derivatives that is different from the mechanism of HCMV resistance to the HPMP derivatives.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874075     DOI: 10.1007/bf01709366

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient.

Authors:  K K Knox; W R Drobyski; D R Carrigan
Journal:  Lancet       Date:  1991-05-25       Impact factor: 79.321

2.  Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

Authors:  W L Drew; R C Miner; D F Busch; S E Follansbee; J Gullett; S G Mehalko; S M Gordon; W F Owen; T R Matthews; W C Buhles
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

3.  Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients.

Authors:  A Erice; S Chou; K K Biron; S C Stanat; H H Balfour; M C Jordan
Journal:  N Engl J Med       Date:  1989-02-02       Impact factor: 91.245

4.  General aspects of virus drug resistance with special reference to herpes simplex virus.

Authors:  D M Coen
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

5.  Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.

Authors:  S C Stanat; J E Reardon; A Erice; M C Jordan; W L Drew; K K Biron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).

Authors:  J Neyts; R Snoeck; D Schols; J Balzarini; E De Clercq
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

7.  Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir.

Authors:  N S Lurain; L E Spafford; K D Thompson
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.

Authors:  J Neyts; J Balzarini; L Naesens; E De Clercq
Journal:  J Med Virol       Date:  1992-05       Impact factor: 2.327

9.  A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.

Authors:  V Sullivan; K K Biron; C Talarico; S C Stanat; M Davis; L M Pozzi; D M Coen
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

10.  A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate.

Authors:  F Baldanti; E Silini; A Sarasini; C L Talarico; S C Stanat; K K Biron; M Furione; F Bono; G Palù; G Gerna
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

View more
  8 in total

1.  Evaluating phenotype and genotype of drug-resistant strains in herpesviruses.

Authors:  G Andrei; P Fiten; E De Clercq; R Snoeck; G Opdenakker
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

2.  Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.

Authors:  Graciela Andrei; Don B Gammon; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck; David H Evans
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.

Authors:  C L Talarico; T C Burnette; W H Miller; S L Smith; M G Davis; S C Stanat; T I Ng; Z He; D M Coen; B Roizman; K K Biron
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 4.  Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

5.  Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.

Authors:  T Cihlar; M D Fuller; J M Cherrington
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Authors:  Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2021-09-21       Impact factor: 5.970

8.  Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.

Authors:  Karine Barral; Clément Weck; Nadine Payrot; Loic Roux; Céline Durafour; Fabien Zoulim; Johan Neyts; Jan Balzarini; Bruno Canard; Stéphane Priet; Karine Alvarez
Journal:  Eur J Med Chem       Date:  2011-07-01       Impact factor: 6.514

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.